Results 11 to 20 of about 4,524 (132)

Exposure-Response Analyses of Ropeginterferon Alfa-2b in Essential Thrombocythemia. [PDF]

J Clin Pharmacol
Abstract Ropeginterferon alfa‐2b is a new‐generation interferon therapy for the treatment of myeloproliferative neoplasms (MPNs), including essential thrombocythemia (ET). This investigation was designed to characterize its population pharmacokinetics–pharmacodynamics (PopPK‐PD) and delineate exposure–response (E‐R) relationships in ET. A population PK
Qin A, Masarova L, Chen H, Xiao Z, Jin J, Gill H, Reeves BN, Chaer FE, Kirito K, Komatsu N, Abu-Zeinah G, Shimoda K, Zagrijtschuk O, Sato T, Wu D, Wu L, Su X, Gao Y, Cui J, Zhang L, Mesa RA.   +20 more
europepmc   +2 more sources

The bidirectional relationship between <i>JAK2V617F</i> allele burden and inflammation in polycythaemia vera: Insights from interferon and ruxolitinib therapy. [PDF]

Hemasphere
HemaSphere, Volume 10, Issue 8, August 2026.
Barbui T, Guglielmelli P, Vannucchi AM.
europepmc   +2 more sources

CO‐Rebreathing in Essential Thrombocythemia and Polycythemia Vera. A Revival of an Old Methodology to Improve Diagnosis and Phlebotomy Decisions [PDF]

Cancer Med
ABSTRACT The diagnostic landscape for the Philadelphia‐negative myeloproliferative neoplasms (MPNs), particularly in distinguishing Essential Thrombocythemia (ET) from Polycythemia Vera (PV), is compromised. The gold standard for diagnosing PV—measurement of red cell mass (RCM) by radioisotope dilution—has been largely abandoned, leading to widespread ...
Hasselbalch H, Larsen M, Løffler L, Andersen C, Davidsen I, Jensen M, Bechlund J, Kjær L, Skov V, Nielsen H, Lundby C.   +10 more
europepmc   +2 more sources

Allele burden expansion in <i>JAK2</i> ^V617F and <i>CALR</i>-mutated myeloproliferative neoplasms predicts disease progression and is associated with anagrelide treatment. [PDF]

Hemasphere
HemaSphere, Volume 10, Issue 9, September 2026.
Ng ZY, Cottin L, Demoy M, Paz DL, Orvain C, Lambert WC, Ianotto JC, Lippert E, Ross DM, Iarossi D, Khan A, Lock D, Truong C, Laribi K, Yang YF, Gagnon LL, Ugo V, Harrison CN, O'Sullivan J.   +18 more
europepmc   +2 more sources

Association of JAK2V617F mutation with thrombosis in Indian patients with Philadelphia negative chronic myeloproliferative neoplasms

Indian Journal of Pathology and Microbiology, 2018
Background: It is still a matter of debate regarding the association of JAK2V617F mutation with thrombosis in BCR-ABL negative CMPN patients. The role of JAK2V617F mutation in increasing the thrombotic risk in CMPNs is yet unequivocal.
Kanwaljeet Singh, Sudha Sazawal, Sunita Chhikara, Manoranjan Mahapatra, Renu Saxena   +4 more
doaj   +1 more source

Erythroid lineage-restricted expression of Jak2V617F is sufficient to induce a myeloproliferative disease in mice

Haematologica, 2012
The JAK2V617F mutation has been found in most cases of Ph-negative myeloproliferative neoplasms. Recent studies have shown that expression of Jak2V617F in the hematopoietic compartment causes marked expansion of erythroid progenitors and their ...
Hajime Akada, Saeko Akada, Robert E. Hutchison, Golam Mohi   +3 more
doaj   +1 more source

Circulating CD133+/–CD34– Have Increased c-MYC Expression in Myeloproliferative Neoplasms

Turkish Journal of Hematology, 2023
Objective: Myeloproliferative neoplasms (MPNs) are hematopoietic stem cell (HSC)-originated diseases with clonal myeloproliferation. The constitutive activation of the JAK/STAT pathway is frequently detected in patients with Philadelphia chromosome ...
İldeniz Uslu Bıçak, Berkay Tokcan, Akif Selim Yavuz, Selçuk Sözer Tokdemir   +3 more
doaj   +1 more source

Vascular endothelial cell expression of JAK2V617F is sufficient to promote a pro-thrombotic state due to increased P-selectin expression

Haematologica, 2019
Thrombosis is the main cause of morbidity and mortality in patients with JAK2V617F myeloproliferative neoplasms. Recent studies have reported the presence of JAK2V617F in endothelial cells of some patients with myeloproliferative neoplasms.
Alexandre Guy, Virginie Gourdou-Latyszenok, Nicolas Le Lay, Claire Peghaire, Badr Kilani, Juliana Vieira Dias, Cécile Duplaa, Marie-Ange Renault, Cécile Denis, Jean Luc Villeval, Yacine Boulaftali, Martine Jandrot-Perrus, Thierry Couffinhal, Chloe James   +13 more
doaj   +1 more source

Impact of JAK2V617F Mutational Status on Phenotypic Features in Essential Thrombocythemia and Primary Myelofibrosis

Turkish Journal of Hematology, 2016
INTRODUCTION: The JAK2V617F mutation is present in the majority of patients with essential thrombocythemia (ET) and primary myelofibrosis (PMF). The impact of this mutation on disease phenotype in ET and PMF is still a matter of discussion.
İpek Yonal, Aynur Dağlar Aday, Başak Akadam Teker, Ceylan Yılmaz, Meliha Nalcacı, Akif Selim Yavuz, Fatma Deniz Sargın   +6 more
doaj   +1 more source

Frequent reduction or absence of detection of the JAK2-mutated clone in JAK2V617F-positive patients within the first years of hydroxyurea therapy

Haematologica, 2008
We analyzed the effect of hydroxyurea on the JAK2V617F allelic ratio (%JAK2V617F), measured in purified blood granulocytes, of patients with polycythemia vera and essential thrombocythemia.
François Girodon, Céline Schaeffer, Cédric Cleyrat, Morgane Mounier, Ingrid Lafont, Frédéric Dos Santos, Aurélie Vidal, Marc Maynadié, Sylvie Hermouet   +8 more
doaj   +1 more source